The predictive and prognostic values of factors associated with visceral pleural involvement in resected lung adenocarcinomas

Huibiao Zhang, Chen Lu, Yingjie Lu, Bo Yu, Fanzhen Lv, Zhenghong Zhu, Huibiao Zhang, Chen Lu, Yingjie Lu, Bo Yu, Fanzhen Lv, Zhenghong Zhu

Abstract

Background: The predictive and prognostic impact of factors associated with visceral pleural invasion (VPI) on survival and recurrence in patients with resected lung adenocarcinomas is not clearly defined.

Patients and methods: A total of 505 consecutive patients with stage Ia-IIIa lung adenocarcinomas treated with radical resection were included. The predominant growth pattern was classified according to the new classification system for lung adenocarcinoma proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society. The correlations of VPI with clinical and pathologic parameters were analyzed.

Results: The incidence of VPI was significantly lower in lepidic predominant group (15.5% vs 4.5%, P<0.001) and higher in solid and micropapillary predominant group (28.6% vs 17.6%, P=0.004 and 14.7% vs 4.2%, P<0.001, respectively). VPI correlated with higher risk in regional postoperative recurrence (hazard ratio, 2.341; 95% confidence interval, 1.564-3.504) and distant recurrence (hazard ratio, 2.193; 95% confidence interval, 1.665-2.89) in surgically resected lung adenocarcinomas. However, when growth patterns of adenocarcinoma were lumped into multivariate analysis, VPI was not a significant independent predictive factor for survival (P=0.854 for overall survival [OS] and P=0.575 for disease-free survival [DFS]) and recurrence (P=0.38 for regional recurrence and P=0.089 for distant recurrence). Of the 95 patients with stage Ib, those who received adjuvant chemotherapy had longer DFS and OS than the patients who received no chemotherapy after surgery. However, these differences in DFS and OS did not reach statistical significance (P=0.063 for DFS, P=0.85 for OS).

Conclusion: VPI was associated with solid and micropapillary histology. In addition, stage Ib patients with solid histologic subtype tumor showed longer DFS and OS, highlighting a potential benefit in this subgroup of patients and necessitating the need for larger clinical trials.

Keywords: TNM stage; follow-up; histologic subtype; lung cancer; visceral pleural invasion.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves for disease-free survival (A, C) and overall survival (B, D) according to predominant growth patterns in 266 patients with lung adenocarcinoma with visceral pleural invasion.
Figure 2
Figure 2
Kaplan–Meier survival curves for DFS and OS by predominant growth patterns and pathological TNM stage in 266 patients with lung adenocarcinoma with VPI. Notes: (A) Cumulative probability of recurrence-free survival in patients with stage I disease stratified by predominant histology and VPI. (B) Cumulative probability of OS in patients with stage I disease stratified by predominant histology and VPI. (C) Cumulative probability of recurrence-free survival in patients with stage II disease stratified by predominant histology and VPI. (D) Cumulative probability of OS in patients with stage II disease stratified by predominant histology and VPI. (E) Cumulative probability of recurrence-free survival in patients with stage III disease stratified by predominant histology and VPI. (F) Cumulative probability of OS in patients with stage III disease stratified by predominant histology and VPI. Abbreviations: DFS, disease-free survival; OS, overall survival; VPI, visceral pleural invasion.
Figure 2
Figure 2
Kaplan–Meier survival curves for DFS and OS by predominant growth patterns and pathological TNM stage in 266 patients with lung adenocarcinoma with VPI. Notes: (A) Cumulative probability of recurrence-free survival in patients with stage I disease stratified by predominant histology and VPI. (B) Cumulative probability of OS in patients with stage I disease stratified by predominant histology and VPI. (C) Cumulative probability of recurrence-free survival in patients with stage II disease stratified by predominant histology and VPI. (D) Cumulative probability of OS in patients with stage II disease stratified by predominant histology and VPI. (E) Cumulative probability of recurrence-free survival in patients with stage III disease stratified by predominant histology and VPI. (F) Cumulative probability of OS in patients with stage III disease stratified by predominant histology and VPI. Abbreviations: DFS, disease-free survival; OS, overall survival; VPI, visceral pleural invasion.
Figure 3
Figure 3
Kaplan–Meier survival curves for disease-free survival (A) and overall survival (B) by adjuvant chemotherapy in 22 solid predominant lung adenocarcinomas with visceral pleural invasion.

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
    1. Chang YL, Lin MW, Shih JY, Wu CT, Lee YC. The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol. 2012;19:3057–3064.
    1. Neri S, Yoshida J, Ishii G, et al. Prognostic impact of microscopic vessel invasion and visceral pleural invasion in non–small cell lung cancer. Ann Surg. 2014;260:383–388.
    1. Hung JJ, Jeng WJ, Hsu WH, Chou TY, Lin SF, Wu YC. Prognostic significance of the extent of visceral pleural invasion in completely resected node-negative non-small cell lung cancer. Chest. 2012;142:141–150.
    1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–714.
    1. Lopez Guerra JL, Gomez DR, Lin SH, et al. Risk factors for local and regional recurrence in patients with resected N0–N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol. 2013;24:67–74.
    1. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest. 2008;133:662–669.
    1. Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang BS, Wu YC. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer. J Thorac Oncol. 2012;7:1115–1123.
    1. Travis WD, Brambilla E, Noguchi M, Hirsch FR, IASLC Pathology Committee International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6:244–285.
    1. Hung JJ, Yeh YC, Jeng WJ, et al. Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32:2357–2364.
    1. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30:1438–1446.
    1. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3:1384–1390.
    1. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371–376.
    1. Mansuet-Lupo A, Bobbio A, Blons H, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014;146:633–643.
    1. Geiger S, Schlemmer M, Heinemann V, Stemmler HJ. Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? Anticancer Drugs. 2010;21:799–804.
    1. Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol. 2005;23:3288–3293.
    1. Schiller JH1, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
    1. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest. 2011;139:855–861.
    1. Oven Ustaalioglu BB, Unal OU, Turan N, et al. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences. Asian Pac J Cancer Prev. 2013;14:6287–6292.
    1. Nitadori J, Colovos C, Kadota K, et al. Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤2 cm: a proposal to reclassify T1 lung adenocarcinoma. Chest. 2013;144:1622–1631.
    1. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion classification in non–small cell lung cancer: A proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg. 2004;127:1574–1578.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel